Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Genomic Medicine at VA Study
Sponsor: Boston VA Research Institute, Inc.
Summary
This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, atrial fibrillation, type 2 diabetes mellitus, colorectal cancer, breast cancer, or prostate cancer), measured by time-to-diagnosis of prevalent or incident disease over 24 months.
Official title: Pragmatic Randomized Trial of Polygenic Risk Scoring for Common Diseases in Primary Care
Key Details
Gender
All
Age Range
50 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
1071
Start Date
2020-07-17
Completion Date
2027-09-30
Last Updated
2026-10-02
Healthy Volunteers
No
Conditions
Interventions
Polygenic risk score (PRS)
Polygenic risk score report from a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory for coronary artery disease, atrial fibrillation, type 2 diabetes, colorectal cancer, breast cancer (for women only), and prostate cancer (for men only), delivered along with patient- and provider-level educational material.
Locations (1)
VA Boston Healthcare System
Boston, Massachusetts, United States